Overview

A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers

Status:
Active, not recruiting

Trial end date:
2024-01-31

Target enrollment:

Participant gender:

Summary

This is a double-blind, comparative, randomized phase I study comparing pharmacokinetics, safety and immunogenicity profiles of a biosimilar pertuzumab (BCD-178) and Perjeta after a single intravenous infusion in healthy male volunteers

Phase:

Phase 1

Details

Lead Sponsor:

Biocad

Treatments:

Pertuzumab